The Learning and Associative Memory (LAM) test is a face-name associative memory test created to detect early Alzheimer's disease (AD). In a recent study, it was administered to cognitively healthy individuals with different levels of amyloid-β (Aβ) and tau burden. The key findings for LAM were: 1) selective correlations with Aβ levels, 2) unique discriminatory power between A + and A- individuals, 3) significantly higher areas under the curve in receiver operating curve analysis. Future research should focus on comparing performance on the LAM and face-name associative memory tests to determine the most effective method for detecting early signs of AD.
CallahanBRamirezJBerezukC, et al.Predicting Alzheimer’s disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers. Alzheimers Res Ther2015; 7: 68.
2.
DukartJSambataroFBertolinoA. Accurate prediction of conversion to Alzheimer’s disease using imaging, genetic, and neuropsychological biomarkers. J Alzheimers Dis2016; 49: 1143–1159.
3.
LuisCAbdullahLAit-GhezalaG, et al.Feasibility of predicting MCI/AD using neuropsychological tests and serum β-amyloid. Int J Alzheimers Dis2011; 2011: 786264. DOI: 10.4061/2011/786264.
4.
PalmqvistSHertzeJMinthonL, et al.Comparison of brief cognitive tests and CSF biomarkers in predicting AD in mild cognitive impairment: six-year follow-up study. PLOS One2012; 7: e38639.
5.
SmithGBondiM. Mild cognitive impairment and dementia. Oxford: Oxford University Press, 2013.
6.
AndrésPVicoHYáñezA, et al.Quantifying memory deficits in amnestic mild cognitive impairment. Alzheimers Dement2019; 11: 108–114.
7.
GrandeGVanacoreNVetranoDL, et al.Free and cued selective reminding test predicts progression to Alzheimer’s disease in people with mild cognitive impairment. Neurol Sci2018; 39: 1867–1875.
8.
RentzDMAmariglioREBeckerJA, et al.Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia2011; 49: 2776–2783.
9.
LoewensteinDACurielREDuaraR, et al.Novel cognitive paradigms for the detection of memory impairment in preclinical Alzheimer's disease. Assessment2018; 25: 348–359.
10.
RubiñoJAndrésP. The face-name associative memory test as a tool for early diagnosis of Alzheimer's disease. Front Psychol2018; 9: 1464.
11.
Vila-CastelarCMuñozNPappKV, et al.The Latin American spanish version of the face-name associative memory exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease. Alzheimers Res Therapy2020; 12: 104.
12.
SanabriaAAlegretMRodriguez-GomezO, et al.The Spanish version of face-name associative memory exam (S-FNAME) performance is related to Aβ burden in subjective cognitive decline. Sci Rep2018; 8: 3828.
13.
AlegretMMuñozNRobertoN, et al.A computerized version of the short form of the face-name associative memory exam (FACEmemory®) for the early detection of Alzheimer's disease. Alzheimers Res Therapy2020; 12: 25.
14.
AlegretMSotolongo-GrauOde AntonioE, et al.Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort. Alzheimers Res Therapy2022; 14: 43.
15.
García-MartinezMPozueta-CantudoALageC, et al.LAM Test: a new cognitive marker for early detection in preclinical Alzheimer’s disease. J Alzheimers Dis2024; 100: 1039–1053.
